Medtronic presents new data on MiniMed 780G system

Medtronic presented a collection of new clinical and real-world data on the MiniMed 780G system. These latest data sets, which evaluated the system across a wide range of users, including historically challenging younger patients, those not meeting glycemic goals, and individuals using a simplified meal announcement leveraging fixed carbohydrate amounts instead of exact carb calculations, found that the proprietary Meal Detection technology supported Time in Range outcomes that exceed consensus guidelines of 70 percent. Additionally, the system is helping reduce the percent of time spent in hyperglycemia in children and adults. These latest results were presented this weekend at the 83rd American Diabetes Association Scientific Sessions in San Diego, CA. The first study randomly assigned adolescents using the MiniMed 780G system into two groups, with some entering a fixed pre-set number of carbs and some calculating a precise number of carbs for their meals. These individuals had lived with diabetes for at least one year and used multiple daily injections or pump therapy prior to the study. Results from the study showed those using the simplified carb entry maintained international targets for glycemic control, including an A1c of 6.9% and Time in Range of 72.7% over 6 months without system modification. Additionally, the simplified entry group lowered their time above 250 mg/dL from 28.3% to 5.3% at six months. After 3 months, 88% chose to continue with the simplified meal management approach, which suggests user satisfaction with this less burdensome approach. These results suggest that reduced accuracy in carb counting can be overcome by the increased automated insulin delivery provided by the MiniMed 780G system, and that even those that cannot or do not input their carbs precisely can reach glycemic goals and reduce hyperglycemia. An analysis of real-world evidence of children less than or equal to 15 years in Europe and Latin America using the MiniMed 780G system with recommended settings of 100 mg/dL and 2-hour active insulin time demonstrated a Time in Range of 78%. A separate analysis of real-world evidence of children less than or equal to 15 years in Europe demonstrated improved glycemic performance in SmartGuard technology regardless of baseline glycemic control. The group with the lowest Time in Range prior to SmartGuard technology, had the largest increase of 23.3% in Time in Range, while patients with the best metabolic control in SmartGuard technology achieved 80.6% Time in Range. Additionally, this increase in Time in Range was seen with less effort as evidenced by fewer user-initiated boluses, indicating decreased patient burden. For the first time, real-world data on the Medtronic Extended Infusion Set was presented and the analysis showed an average infusion set wear time of 6.74 days. Almost half of the individuals evaluated wore the set for 7 days. This real-world data mirrors the results from the U.S. pivotal trial and is delivering a reduced user burden through less frequent infusion set changes.